bronchitis%20-%20chronic%20in%20acute%20exacerbation
BRONCHITIS - CHRONIC IN ACUTE EXACERBATION

Chronic bronchitis is an infection of the trachea and bronchi for at least 3 consecutive months for more than 2 consecutive years.
The patient experiences symptoms of increase in dyspnea, sputum volume and sputum purulence over baseline on most days.

Diagnosis is basically based on clinical presentation.

Supportive Therapy

Supportive Therapy

Hydration

  • Maintain adequate hydration to prevent excessive mucus viscosity

Nutritional Programs

  • There are no direct or measurable effects on lung function in treating malnutrition but subjective relief & objective improvement in strength & exercise performance do occur
    • Dietary supplementation should be considered if patient is malnourished (body weight <85% of ideal) or experiencing early satiety
  • Advise patient to obtain nutritional counseling to reduce weight if obese

Oxygen Therapy

  • Cornerstone of COPD exacerbation treatment
  • Low-flow O2 should be administered if hypoxemia is present
  • Excess use of O2 should be avoided as this may lead to progressive hypercapnia, either by decreasing hypoxic ventilatory drive or by worsening ventilation-perfusion mismatching within the lung
  • Once O2 therapy is initiated, arterial blood gas should be monitored 30-60 minutes later to ensure satisfactory oxygenation without acidosis or CO2 retention
  • Goal of supplemental O2 therapy should be arterial blood gas at or just above 60 mmHg

Noninvasive Positive Pressure Ventilation

  • Frequently used for inpatient management of AECB patients who are significantly hypoxemic or with a serum pH <7.3
  • Improves ventilation and lower pCO2 levels and may be a means of avoiding intubation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Audrey Abella, 21 Jul 2017
Deficiency in vitamin A (<200 µg/L) may predict the risk of incident tuberculosis (TB) in individuals with household exposure to a person with TB, a recent study has found.
14 Mar 2016
Delamanid may be a potent treatment regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) patients, based on a study.
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Dr Joslyn Ngu, 16 Oct 2017

The main goal of the National Strategic Plan (NSP) for TB Control (2016 to 2020) is to reduce tuberculosis (TB) burden by ensuring universal access to timely and quality diagnosis and treatment of all types of TB, and preventing the development of drug resistant TB, says an expert.